Filter by:
Topic
Resource Type
Display Only
Showing 70 Results
Continuing Innovation for Rare Conditions Under the Orphan Drug Act
The Orphan Drug Act has served as a catalyst for the development of many innovative therapies to treat rare diseases. Without the appropriate incentives to develop therapies for rare or ultra-rare…
Innovating to Help Patients with Rare Diseases
One out of every 10 Americans live with a rare disease. Rare Disease Week serves as a reminder of their many needs and challenges and the work that researchers, clinicians, and our member companies…
What If Groundbreaking Medicines Never Existed?
New research from estimates what health gains might have been lost without the introduction of influential innovations for six serious diseases.
What Might Have Happened: The Impact of Interrupting Entry of Innovative Drugs on Disease Outcomes in the United States
A new NPC study shows how major drug innovations significantly improved patient health outcomes for six diseases with substantial mortality or morbidity.
Value Assessment’s ‘Leaky Bucket’ Problem
In Health Affairs Forefront, NPC outlines the challenges in assessing the value of new treatments and proposes a framework and recommendations to ensure patient access to new therapies and continued…
Creating a Dialogue or Just Playing for Headlines? Third Time Isn’t the Charm for ICER’s Pricing Report
Selectively picking the data to arrive at a convenient narrative — like the Institute for Clinical and Economic Review does in its third drug pricing report — should not be mistaken for good research.
Chairman’s Blog: Five Questions Decision-Makers Should Be Asking About Health Technology Agencies
NPC Board Chair and BMS SVP Michael Ryan advises caution and careful consideration of the potential risks and tradeoffs for patients by using a centralized, government-run health technology agency …
At the Heart of It: How Innovation Drives Improved Patient Outcomes
In honor of World Heart Day, NPC looks at how innovative medical interventions have vastly improved cardiovascular disease outcomes.
Working Together to Deliver Innovation for Patients During COVID-19 and Beyond
What's at risk if we limit innovation? Read the commentary from NPC's John O'Brien in Chain Drug Review.
On World Hepatitis Day, Looking at Innovation That Goes Beyond a Pill
Michael Ciarametaro, Vice President of Research at NPC, reflects on how the scientific revolution of hepatitis C led to a corresponding reimbursement revolution that became a fertile ground for large…
The Trade-off for Price Controls: Are We Willing to Accept Fewer Medicines?
It's possible to strike a balance between innovation and efficient spending, and to implement policies ensuring that resources are being invested in treatments, procedures and public health efforts…
AMCP Partnership Forum: Preparing for and Managing Rare Diseases
Stakeholders met virtually for an AMCP Partnership Forum to discuss viable solutions to challenges facing people living with rare disorders, such as affordable and timely access to therapies,…
ICER Pricing Report: Creating a Dialogue or Just Playing for Headlines?
Given declines in drug prices, the Institute for Clinical and Economic Review’s second report on drug pricing – focusing on a hand-picked, narrow group of medicines rather than the overall landscape …
Empowering the Patient Voice in Value Assessment: Paving the Way for MCDA
The National Health Council (NHC) and National Pharmaceutical Council (NPC) co-hosted a webinar that explored how multi-criteria decision-making analysis (MCDA) can be used in value assessment.
NPC Patient-Reported Measures Research Featured at AMCP Nexus 2020
A panel at the Academy of Managed Care Pharmacy Nexus 2020 explored the tension between patient-reported measures funding and innovation and highlighted published research by NPC and Discern Health.
Multi-Criteria Decision Analysis: A Way to Put Patient Concerns Front and Center in Value Assessment?
NHC and NPC released a white paper outlining multi-criteria decision analysis (MCDA), an approach to value assessment that may more holistically address patients’ concerns, experiences and treatment…
Multi-Criteria Decision Analysis: Can It Help Make Value Assessment More Patient Centered?
This white paper identifies good practices and key considerations for integrating the patient voice into patient-centered multi-criteria decision analysis.
IVI's Jennifer Bright on Value Assessment and Transparency
In an interview, Innovation and Value Initiative Executive Director Jennifer Bright discusses how her organization has been advancing value assessment practice and the key priorities to make the…
Will the Pandemic Provide the Push for Positive Change?
NPC President and CEO Dan Leonard considers the COVID-19 pandemic and its impact on our health care system, as well as whether we’ll see continued innovation in how we access, administer and pay for…
Experts Advise Including Productivity in Value Assessment Frameworks – When Included, It Can Make a Difference
NPC researchers sought to assess if productivity is included in VAF analyses, when included, does it change the value assessment of an intervention, and if including productivity could change health…